Welcome to our dedicated page for Essa Pharma SEC filings (Ticker: EPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, shifting cash burn, and abrupt program terminations make ESSA Pharma鈥檚 SEC documents challenging to decode. If you鈥檝e searched 鈥淓SSA Pharma SEC filings explained simply鈥� or asked how to track masofaniten updates inside a terse 8-K, you know the struggle鈥攁nd the stakes.
Stock Titan鈥檚 AI ends that friction. Our engine converts the 200-page 鈥淓SSA Pharma annual report 10-K simplified鈥� into a plain-English brief, highlights cash-runway tables, and flags every risk-factor change. Looking for the latest 鈥淓SSA Pharma quarterly earnings report 10-Q filing鈥�, or need instant alerts on 鈥淓SSA Pharma insider trading Form 4 transactions鈥�? We pull each document directly from EDGAR, parse the science and the numbers, and surface what matters first.
Use the platform to:
- Follow 鈥淓SSA Pharma Form 4 insider transactions real-time鈥� and spot buying or selling before clinical news breaks.
- Compare leadership incentives by scanning the 鈥淓SSA Pharma proxy statement executive compensation鈥�.
- Read 鈥淓SSA Pharma 8-K material events explained鈥� to understand why trials pause, pivot, or stop.
Whether you need an 鈥淓SSA Pharma earnings report filing analysis鈥�, insight into dilution risk, or simply guidance on 鈥渦nderstanding ESSA Pharma SEC documents with AI,鈥� Stock Titan delivers comprehensive, real-time coverage and clarity you can trust.
ESSA Pharma Inc. announced a return of capital distribution totaling US$80,000,000 tied to its previously disclosed transaction under which non-profit XenoTherapeutics, Inc. will acquire all issued and outstanding common shares. The company said shareholders will receive approximately $1.69 per common share (subject to applicable withholding).
Nasdaq has set the ex-dividend date for the distribution as August 25, 2025, and the Distribution is scheduled to be paid on August 22, 2025. The filing notes that common shares will trade with a "due bill" during the period between the payment date and the ex-dividend date, meaning assignment of the right to receive the Distribution remains with the shares through the due bill period.
ESSA Pharma (EPIX) reported interim results as of June 30, 2025 showing a strong cash position and a major strategic shift. The company held $85.95 million in cash and $23.67 million in short-term U.S. Treasury securities, giving working capital of $108.90 million and total assets of $110.50 million. ESSA recorded a net loss of $18.91 million for the nine months ended June 30, 2025 and an accumulated deficit of $226.91 million. In October 2024 ESSA terminated clinical trials of its lead candidate, masofaniten (EPI-7386), and withdrew related IND/CTA filings. Subsequent to the quarter, ESSA entered a Business Combination Agreement with XenoTherapeutics under which shareholders are currently estimated to receive approximately US$1.91 per share plus one non-transferable contingent value right (CVR) per share entitling holders to a pro rata portion of up to US$2.95 million (up to US$0.06 per CVR). The Transaction requires court and shareholder approvals and is expected to close in the second half of 2025.
ESSA Pharma (EPIX) is asking Securityholders to approve a court鈥慳pproved Plan of Arrangement to be voted on at a virtual Special Meeting on September 10, 2025. Under the Arrangement, Xeno Acquisition Corp. (a subsidiary of XenoTherapeutics) will acquire all outstanding common shares for an estimated Cash Amount of approximately US$1.91 per share (subject to reduction by a Distribution) plus one CVR per share entitling holders to a pro鈥憆ata portion of up to US$2,950,000 less specified deductions related to litigation and costs.
The Board and an independent Transaction Committee unanimously recommend the Arrangement and received a fairness opinion from Leerink Partners dated July 13, 2025. The Company received court authorization for a concurrent capital reduction and a proposed aggregate Distribution of US$80,000,000 (scheduled on or about August 22, 2025). As of the Record Date (August 5, 2025) there were 44,338,550 common shares outstanding, 7,830,523 Options and 2,920,000 Warrants. Closing is expected on or about September 18, 2025, after required shareholder votes and court orders, and will result in delisting from Nasdaq and deregistration under the Exchange Act.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
